Fingolimod treatment in multiple sclerosis leads to increased macular volume.

ABSTRACT:

Objective

To determine whether fingolimod, an oral sphingosine-1-phosphate receptor modulator approved for treatment of multiple sclerosis (MS), generally leads to increased retinal tissue volume.

Methods

In this longitudinal observational study, we compared changes in macular volume on spectral-domain optical coherence tomography (OCT) between consecutive patients with MS who initiated fingolimod and a matched reference cohort of patients with MS never exposed to the drug. The primary reference cohort was matched based on time interval between OCT examinations. A secondary reference cohort was matched based on age and disease duration. Change in macular volume within each group was analyzed using the paired t test. Change in macular volume between groups was examined using

SUBMITTER: Nolan R 

PROVIDER: S-EPMC3589191 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature